Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
Sponsor: GlaxoSmithKline
A PHASE2 clinical study on Fallopian Tube Cancer and High Grade Endometrioid Cancer, this trial is ongoing. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Feb 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .